B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 75.5%

Neg 0% Neu 0% Pos 75.5%

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $11 to $13.